- RecruitingPHASE2
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
This study is looking at a new drug called neflamapimod for people with a rare form of dementia called nonfluent variant primary progressive aphasia (nfvPPA). We want to see if it's safe and how it affects their language and thinking.
For: Nonfluent Variant Primary Progressive Aphasia (nfvPPA)United States · United Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
This study is looking at a new medicine called neflamapimod for people with a type of memory problem called Dementia with Lewy Bodies (DLB). It aims to see if this medicine can help improve memory and thinking over 16 weeks.
For: Subjects aged ≥55 years with probable Dementia with Lewy Bodies DLB by consensus criteria (McKeith et al · including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negative · but the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD)Netherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
This study is testing a new medicine, neflamapimod, for people with a type of memory problem called Dementia with Lewy Bodies (DLB). It's looking at how safe the medicine is and how the body handles it, along with whether it helps with symptoms.
For: Dementia with Lewy Bodies (DLB)France